Abiopharma

OKYO Pharma (OKYO) Files Form 6-K

Director Gilad Oren 🟢 acquired 42.9K shares (2 derivative) of Aprea Therapeutics, Inc. (APRE) at $1.04 Transaction Date: Dec 10, 2025 | Filing ID: 120152

Baxter Presents Real-World Data at American Society of Health System Pharmacists Meeting Demonstrating Smart Infusion Pump Electronic Medical Record (EMR) Integration May Improve Patient Safety and Nursing Bedside Productivity

HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1

OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

(90% Positive) Cadrenal Therapeutics, Inc. (CVKD) Provides Update on opportunity for clinical testing

(99% Neutral) CLIMB BIO, INC. (ELYM) Announces Business Combination

(70% Positive) TRANSCODE THERAPEUTICS, INC. (RNAZ) Announces Clinical Development Update

Biomerica, Inc. - Egyptian Drug Authority AuthorizesBiomerica’s Complete Screening Test Portfolio

Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio

Innovative Eyewear, Inc. Announces New Reebok® Smart Eyewear for Gym and Indoor Sports

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Guardant Health, Inc. - Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.

Savara Inc. - Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*